Vitamin K Market Size, Share, Growth, and Industry Analysis, By Type (Vitamin K1,Vitamin K2), By Application (Osteoporosis,Vitamin-K Dependent Clotting Factor Deficiency [VKCFD],Dermal Applications,Prothrombin Deficiency,Vitamin K Deficiency Bleeding [VKDB]), Regional Insights and Forecast to 2035

Vitamin K Market Overview

The global Vitamin K Market in terms of revenue was estimated to be worth USD 1200.05 Million in 2026 and is poised to reach USD 1954.37 Million by 2035, growing at a CAGR of 5.57% from 2026 to 2035.

The global Vitamin K Market is witnessing a sharp rise in demand across pharmaceutical, nutraceutical, and food sectors due to increased awareness of health supplements. In 2024, global vitamin K production volume exceeded 6,500 metric tons, with over 38% attributed to pharmaceutical applications. Vitamin K2 is gaining significant traction, accounting for nearly 55% of the total vitamin K product sales. Among all countries, China dominated the supply chain, contributing to over 41% of global vitamin K output. As of 2024, the global vitamin K export volume surpassed 3,000 metric tons. With consistent product innovation, the market is forecasted to expand substantially in terms of volume and adoption.

In the United States, the Vitamin K Market is experiencing strong momentum, with over 1,420 metric tons of vitamin K products consumed in 2024 alone. Dietary supplement demand drives nearly 52% of all vitamin K intake nationwide. Vitamin K2 variants dominate 61% of the U.S. market share due to growing interest in cardiovascular and bone health. The pharmaceutical sector contributes to 37% of domestic vitamin K utilization. California, Florida, and New York remain the leading states for vitamin K supplement sales. U.S. imports of vitamin K products surpassed 800 metric tons in 2024, sourced primarily from Europe and Asia.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Increasing demand from the pharmaceutical sector accounts for 39% of global vitamin K market growth.
• Major Market Restraint: Limited awareness in underdeveloped regions impacts 26% of potential market expansion.
• Emerging Trends: The growing focus on Vitamin K2 drives 57% of new product formulations.
• Regional Leadership: Asia-Pacific holds 42% of the global market share in 2024.
• Competitive Landscape: Top five companies command 46% of total market share in 2024.
• Market Segmentation: The Vitamin K1 segment represents 48%, while Vitamin K2 holds 52% of the global market in 2024.
• Recent Development: Over 29% of companies introduced new Vitamin K formulations between 2023 and 2025.

Vitamin K Market Latest Trends

The Vitamin K Market Report highlights a rising preference for Vitamin K2 over K1 due to enhanced bioavailability. By 2024, Vitamin K2 accounted for over 60% of new product launches across dietary supplement brands. The market has seen increased R&D investments, with over 150 clinical trials investigating Vitamin K's efficacy in bone and cardiovascular health. North America and Asia-Pacific lead in these clinical studies. Functional foods and beverages fortified with Vitamin K grew by 27% globally in 2024. There’s also a significant rise in vegan and organic vitamin K products, now representing 18% of the market. The inclusion of menaquinone-7 (MK-7) in multivitamin complexes has grown 32% year-on-year. Personalized nutrition and AI-driven supplement plans have accelerated market innovation. The expansion of e-commerce channels accounted for 34% of global vitamin K supplement sales in 2024.

Vitamin K Market Dynamics

DRIVER

"Rising demand for pharmaceuticals"

The pharmaceutical sector remains a primary driver for the Vitamin K Market Growth. In 2024, over 40% of vitamin K products were absorbed by pharmaceutical manufacturers. Increased incidences of blood clotting disorders and osteoporosis have contributed to this rise. Vitamin K1 (phylloquinone) is increasingly being used in prescription drugs, while Vitamin K2 (menaquinone) is a staple for managing bone-related conditions. Additionally, injectable vitamin K formulations for treating VKDB (Vitamin K Deficiency Bleeding) in newborns have surged in volume. In the U.S. alone, hospitals administered over 2.1 million vitamin K injections in 2024. This growth is also driven by policy recommendations on neonatal care and anticoagulant management.

RESTRAINT

"Demand for refurbished equipment"

Despite growing demand, limited access to high-quality manufacturing and extraction equipment in developing countries is a key restraint. Over 22% of small and mid-level vitamin K manufacturers reported inadequate facilities to process vitamin K2 efficiently. The lack of infrastructure in parts of Africa and Southeast Asia hinders local production. Furthermore, outdated fermentation technology has impacted product yield by nearly 19% across low-income nations. Regulatory complexities for vitamin classification as pharmaceuticals versus supplements also delay product approval timelines by 12 to 18 months, further impeding market expansion in emerging regions.

OPPORTUNITY

"Growth in personalized medicines"

Personalized medicine presents an enormous opportunity for the Vitamin K Market. In 2024, over 18% of all vitamin K supplements in North America were tailored based on genetic and metabolic profiles. DNA-driven supplementation services integrating vitamin K2 into personalized daily packs have grown 45% year-on-year. Wearable devices and health-tracking apps syncing with supplement plans now influence over 21% of vitamin purchases. Companies like Kappa Bioscience are investing in nutrigenomics to formulate precision vitamin K solutions. The opportunity to integrate vitamin K into digital health platforms will help penetrate urban wellness markets and strengthen product positioning among millennial consumers.

CHALLENGE

"Rising costs and expenditures"

The rising cost of raw materials and production remains a major challenge. In 2024, the cost of synthetic production of vitamin K1 increased by 11%, while fermentation-derived vitamin K2 costs jumped 14% due to microbial strain procurement. Packaging and logistics costs rose 9% globally, impacting supply chains. Environmental regulations in Europe further complicated vitamin extraction processes, increasing compliance costs by 7%. Import tariffs and export restrictions in key producing countries like China disrupted availability in Q3 2024. These factors combined have impacted the pricing strategies of over 33% of global supplement brands.

Vitamin K Market Segmentation

The Vitamin K Market is segmented by type and application to better target customer-specific needs. By type, Vitamin K1 and Vitamin K2 dominate the product landscape. By application, usage spans across osteoporosis, clotting disorders, skin applications, prothrombin deficiency, and neonatal care. As of 2024, 52% of market value stemmed from Vitamin K2, with osteoporosis treatments comprising 38% of total applications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Vitamin K1: Vitamin K1, or phylloquinone, is primarily plant-derived and accounts for 48% of the global vitamin K market in 2024. It is widely used in pharmaceutical and hospital settings for reversing anticoagulant overdoses. Over 2.4 billion vitamin K1 tablets were dispensed globally in 2024, with North America accounting for 33% of usage. It is the preferred choice for neonatal injections, with over 3.8 million global administrations recorded in 2024. Vitamin K1 is also utilized in fortified food products, representing 19% of functional food inclusions.

The Vitamin K1 segment is expected to grow from USD 654.27 million in 2025 to USD 1,009.27 million by 2034, accounting for a 54.51% market share and registering a CAGR of 5.01%, driven by demand in pharmaceutical and dietary supplements.

Top 5 Major Dominant Countries in the Vitamin K1 Segment

• United States: The U.S. Vitamin K1 market will reach USD 294.85 million by 2034, holding 29.22% share with a CAGR of 5.03% due to strong demand in prescription and over-the-counter drug formulations.
• China: China is projected to grow to USD 221.63 million by 2034, accounting for 21.96% market share and a CAGR of 5.08%, supported by mass-scale supplement production and export.
• Germany: Germany will attain USD 144.27 million by 2034, securing a 14.29% share and 5.01% CAGR from expanding therapeutic applications and hospital demand.
• Japan: Japan is forecasted to hit USD 130.61 million by 2034, representing a 12.94% share and 4.95% CAGR, led by aging-related bone care solutions.
• Brazil: Brazil will reach USD 117.09 million by 2034, with a 11.61% market share and 4.97% CAGR through increased use in multivitamin formulations.

Vitamin K2: Vitamin K2, or menaquinone, dominates the market with 52% share in 2024, driven by its bioavailability and longer half-life. It is extensively used in bone health supplements, cardiovascular support, and functional foods. In Japan, over 42% of vitamin K2 formulations are prescribed for osteoporosis management. MK-7, a subtype of K2, contributed to 63% of all vitamin K2 sales. The Asia-Pacific region led the K2 market with over 800 metric tons sold in 2024. K2's fermentation-based production is increasing in Europe, contributing 36% of regional K2 output.

The Vitamin K2 segment is projected to increase from USD 482.46 million in 2025 to USD 841.98 million by 2034, registering a CAGR of 6.27%, and capturing a 45.49% share, fueled by cardiovascular and osteoporosis-focused formulations.

Top 5 Major Dominant Countries in the Vitamin K2 Segment

• United States: The U.S. Vitamin K2 market will reach USD 278.36 million by 2034, securing 33.05% share and 6.30% CAGR, driven by aging population health supplements.
• Germany: Germany will post USD 159.34 million by 2034, capturing 18.92% market share and a CAGR of 6.22% due to high adoption in specialty nutraceuticals.
• China: China will reach USD 148.22 million by 2034, with 17.60% share and 6.31% CAGR as health-conscious consumer demand rises.
• Japan: Japan will grow to USD 132.67 million by 2034, holding 15.75% share and 6.19% CAGR, supported by preventive bone health treatments.
• India: India is expected to attain USD 123.39 million by 2034, accounting for 14.65% market share with 6.25% CAGR from fortified nutrition expansion.

BY APPLICATION

Osteoporosis: Vitamin K is critical in calcium regulation, making it essential in osteoporosis treatment. In 2024, over 38% of vitamin K applications globally targeted osteoporosis. In Europe, more than 22 million elderly individuals were prescribed K2 supplements for bone health. Japan led in prescription-based osteoporosis use, with over 14 million doses recorded in 2024. Clinical studies validate K2’s role in preventing bone fractures and enhancing bone density.

The Osteoporosis segment is forecasted to grow from USD 343.76 million in 2025 to USD 588.67 million by 2034, securing a 31.80% share and a CAGR of 6.16%, due to rising elderly population and preventive healthcare focus.

Top 5 Major Dominant Countries in the Osteoporosis Application

• United States: The U.S. market will reach USD 191.67 million by 2034, capturing 32.56% share and 6.20% CAGR driven by high prevalence of age-related bone diseases.
• Japan: Japan will achieve USD 109.38 million by 2034, securing 18.57% share and 6.12% CAGR due to dietary supplementation trends in seniors.
• Germany: Germany will grow to USD 93.45 million by 2034, holding 15.87% share and 6.14% CAGR from rising elderly-focused healthcare policies.
• China: China will reach USD 88.93 million by 2034, with 15.11% share and 6.17% CAGR supported by growing orthopedic healthcare awareness.
• Brazil: Brazil will post USD 77.89 million by 2034, comprising 13.23% share and 6.10% CAGR through public health osteoporosis programs.

Vitamin-K Dependent Clotting Factor Deficiency (VKCFD): VKCFD treatment relies heavily on Vitamin K1 formulations. In 2024, around 19,000 new VKCFD cases were diagnosed globally, and over 4.2 million vitamin K1 vials were distributed. North America and Europe accounted for 67% of VKCFD therapy. Hospitals are now integrating K1 into emergency coagulation kits, accounting for 24% of K1’s medical application volume.

VKCFD segment is projected to rise from USD 254.43 million in 2025 to USD 392.17 million by 2034, accounting for a 21.18% market share and a CAGR of 4.93%, driven by rare disease treatment programs.

Top 5 Major Dominant Countries in the VKCFD Application

• United States: The U.S. will reach USD 127.29 million by 2034, holding 32.46% share and 4.94% CAGR due to diagnostic screening and newborn deficiency treatment protocols.
• Germany: Germany will grow to USD 78.94 million by 2034, securing 20.13% market share and 4.91% CAGR with advanced clinical programs.
• Japan: Japan is forecasted to attain USD 65.77 million by 2034, with a 16.77% share and 4.92% CAGR supported by early-stage detection systems.
• United Kingdom: The U.K. will reach USD 61.32 million by 2034, capturing 15.64% share and 4.89% CAGR from rare disorder initiatives.
• Canada: Canada will hit USD 58.85 million by 2034, reflecting 15.01% share and 4.88% CAGR through targeted research investments.

Dermal Applications: Vitamin K creams and topicals are used for treating bruises, scars, and skin discoloration. Dermal use accounted for 14% of global vitamin K application in 2024. Over 92 brands introduced vitamin K-based skincare products between 2023 and 2025. The U.S. skincare industry absorbed 270 metric tons of vitamin K ingredients. Asia-Pacific is witnessing growing demand in K-beauty formulations.

The Dermal Applications segment will increase from USD 192.24 million in 2025 to USD 327.43 million by 2034, capturing 17.69% share and registering a CAGR of 6.05%, fueled by use in post-surgical healing and skincare.

Top 5 Major Dominant Countries in the Dermal Applications

• United States: The U.S. dermal market will reach USD 102.29 million by 2034, holding 31.25% share and 6.08% CAGR due to demand in topical vitamin formulations.
• France: France will grow to USD 71.83 million by 2034, capturing 21.94% share and 6.00% CAGR through cosmeceutical applications.
• South Korea: South Korea will post USD 55.42 million by 2034, securing 16.93% share and 6.10% CAGR from beauty and healing creams.
• Japan: Japan will hit USD 52.31 million by 2034, accounting for 15.98% share and 5.98% CAGR from anti-aging and dermal recovery products.
• Germany: Germany will achieve USD 45.58 million by 2034, comprising 13.93% share and 6.03% CAGR through medicated cosmetic product innovation.

Prothrombin Deficiency: This rare bleeding disorder saw over 12,000 new cases globally in 2024. Vitamin K injections were administered in 86% of hospital-based prothrombin cases. Hospitals in the U.K. and Germany reported a 17% rise in K1-based therapy adoption. Emergency kits in ambulances now include vitamin K vials as standard protocol across 11 European countries.

The Prothrombin Deficiency segment is estimated to grow from USD 173.62 million in 2025 to USD 272.11 million by 2034, accounting for 14.70% market share and a CAGR of 5.18%, due to heightened testing and treatments.

Top 5 Major Dominant Countries in the Prothrombin Deficiency Application

• United States: The U.S. market will reach USD 101.74 million by 2034, holding 37.37% share and 5.21% CAGR through improved blood coagulation therapies.
• Germany: Germany is projected to hit USD 62.13 million by 2034, with 22.83% share and 5.15% CAGR via clinical diagnostics and treatments.
• Japan: Japan will post USD 49.21 million by 2034, representing 18.09% share and 5.14% CAGR due to high per-capita hospital spending.
• Italy: Italy will attain USD 36.93 million by 2034, securing 13.57% share and 5.17% CAGR from hereditary treatment innovations.
• Brazil: Brazil will reach USD 33.92 million by 2034, comprising 12.46% share and 5.13% CAGR from investments in blood disorder research.

Vitamin K Deficiency Bleeding (VKDB): Newborns with VKDB are treated with prophylactic vitamin K1. Over 25 million infants globally received vitamin K prophylaxis in 2024. Neonatal hospitals in India and Brazil recorded over 3 million intramuscular injections. The WHO recommends K1 usage in all births, and this has led to a 90% reduction in VKDB fatalities globally.

The VKDB segment will rise from USD 172.68 million in 2025 to USD 270.87 million by 2034, contributing 14.63% share and a CAGR of 5.22%, largely driven by newborn vitamin K prophylaxis initiatives.

Top 5 Major Dominant Countries in the VKDB Application

• United States: The U.S. VKDB segment will reach USD 104.51 million by 2034, holding 38.58% share and 5.25% CAGR from newborn injectable protocols.
• China: China is expected to grow to USD 62.13 million by 2034, capturing 22.94% market share and 5.20% CAGR with state-run neonatal care expansion.
• Germany: Germany will post USD 43.88 million by 2034, reflecting 16.20% share and 5.18% CAGR via preventative pediatric healthcare.
• India: India will achieve USD 35.41 million by 2034, representing 13.07% share and 5.21% CAGR through expanded maternal-child health programs.
• Japan: Japan will grow to USD 25.93 million by 2034, comprising 9.57% share and 5.19% CAGR due to hospital-based deficiency screening.

Vitamin K Market Regional Outlook

Europe captured 26% of the global Vitamin K Market share in 2024, with Germany distributing 1.6 billion units and Italy and Spain increasing K2 usage by 21% in fortified foods. Asia-Pacific held 32% of the market, led by over 1,500 metric tons in sales from China and Japan, while India recorded 4.5 million neonatal doses. The Middle East & Africa accounted for 8% share, with imports exceeding 120 metric tons in South Africa, UAE, and Egypt due to rising hospital and neonatal demand.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Vitamin K Market with 34% share in 2024, attributed to high supplement consumption and pharmaceutical applications. The U.S. accounts for 82% of the regional market. In Canada, over 45% of adults over age 60 consumed vitamin K supplements in 2024. The region has over 180 vitamin K-based brands. Hospitals administered more than 2 million doses in 2024. E-commerce channels accounted for 44% of total supplement sales in North America. The region is home to major players such as Amway and Pfizer.

The North America Vitamin K Market is projected to grow from USD 386.21 million in 2025 to USD 607.87 million by 2034, accounting for 32.83% of the global market share and a CAGR of 5.27%. Growth is supported by high healthcare spending, increased supplementation, and strong clinical research infrastructure.

North America - Major Dominant Countries in the “Vitamin K Market”

• United States: The U.S. market will reach USD 502.88 million by 2034, holding 82.72% share and a CAGR of 5.30%, driven by leading supplement brands and newborn prophylaxis programs.
• Canada: Canada will grow to USD 59.12 million by 2034, accounting for 9.72% share and a CAGR of 5.24% due to preventive care awareness and healthy aging demand.
• Mexico: Mexico will post USD 25.67 million by 2034, securing 4.22% share and 5.18% CAGR through national nutrition programs and affordable supplement access.
• Guatemala: Guatemala is projected to hit USD 12.11 million by 2034, capturing 1.99% share with a 5.11% CAGR from rural supplementation outreach.
• Costa Rica: Costa Rica will reach USD 8.09 million by 2034, representing 1.33% share and a 5.07% CAGR due to fortified nutrition product growth.

EUROPE

Europe accounts for 26% of the global Vitamin K Market share in 2024. Germany, the U.K., and France are the leading contributors. Germany alone dispensed over 1.6 billion vitamin K units in 2024. The EU implemented updated vitamin K regulations, boosting pharmaceutical product adoption by 14%. Vitamin K2’s integration in food and beverage saw a 21% increase in Italy and Spain. European skincare brands launched over 40 new products featuring vitamin K in 2024.

The Europe Vitamin K Market will expand from USD 312.81 million in 2025 to USD 510.91 million by 2034, achieving a 27.61% market share and a CAGR of 5.67%. Demand is fueled by increasing aging population and medical-grade nutrition products.

Europe - Major Dominant Countries in the “Vitamin K Market”

• Germany: Germany will lead with USD 168.52 million by 2034, capturing 32.98% share and 5.66% CAGR driven by nutraceutical and pharmaceutical integration.
• France: France will grow to USD 110.36 million by 2034, securing 21.60% share and 5.62% CAGR via dermal and clotting applications.
• United Kingdom: The U.K. will post USD 91.42 million by 2034, holding 17.89% share and 5.68% CAGR supported by national health guidelines.
• Italy: Italy will attain USD 75.29 million by 2034, representing 14.74% share and a CAGR of 5.64% from pediatric supplementation.
• Spain: Spain is expected to reach USD 65.32 million by 2034, with 12.78% share and 5.59% CAGR due to rising demand for osteoporotic treatment supplements.

ASIA-PACIFIC

Asia-Pacific holds 32% of the Vitamin K Market share. China and Japan dominate the region, together contributing over 1,500 metric tons of vitamin K sales. India recorded 4.5 million neonatal administrations in 2024. South Korea’s dermal application products contributed to 15% of the vitamin K cosmetic segment. K2-based therapies were adopted in 41% of osteoporosis patients in Japan. Local companies are investing in fermentation-based K2 production, increasing the regional supply by 22% year-on-year.

The Asia Vitamin K Market is forecasted to rise from USD 317.91 million in 2025 to USD 576.83 million by 2034, contributing 31.16% market share and registering a CAGR of 6.79%. Growth is driven by massive population, aging demographics, and government-backed nutrition initiatives.

Asia - Major Dominant Countries in the “Vitamin K Market”

• China: China will dominate with USD 224.19 million by 2034, accounting for 38.87% share and 6.83% CAGR due to large-scale infant healthcare and vitamin K manufacturing.
• Japan: Japan will reach USD 133.92 million by 2034, securing 23.22% share and 6.73% CAGR through strong demand in elderly healthcare.
• India: India will grow to USD 102.65 million by 2034, holding 17.79% share and 6.78% CAGR from government-led nutrition drives.
• South Korea: South Korea will achieve USD 69.54 million by 2034, comprising 12.06% share and 6.72% CAGR due to expanding medical and cosmetic sectors.
• Indonesia: Indonesia will post USD 46.53 million by 2034, capturing 8.06% share and 6.70% CAGR with rising maternal and child health interventions.

MIDDLE EAST & AFRICA

Middle East & Africa holds 8% of the global market share. South Africa, UAE, and Egypt are leading markets in the region. In 2024, vitamin K imports exceeded 120 metric tons. Government neonatal health programs in Kenya and Nigeria boosted vitamin K1 demand by 17%. Pharmaceutical companies are entering long-term agreements with global players to supply injectable K1. Awareness programs improved vitamin K supplement consumption by 23% compared to 2023.

The Middle East and Africa Vitamin K Market is expected to grow from USD 119.80 million in 2025 to USD 155.64 million by 2034, accounting for 8.41% share and registering a CAGR of 2.97%. Market expansion is supported by newborn care programs and fortified health product consumption.

Middle East and Africa - Major Dominant Countries in the “Vitamin K Market”

• United Arab Emirates: UAE will reach USD 41.07 million by 2034, with 26.39% share and a CAGR of 3.03% driven by modern health and wellness trends.
• Saudi Arabia: Saudi Arabia will post USD 36.52 million by 2034, securing 23.47% share and 2.95% CAGR from hospital-grade pharmaceutical usage.
• South Africa: South Africa will achieve USD 29.61 million by 2034, capturing 19.03% share and 2.89% CAGR due to public healthcare supplementation.
• Egypt: Egypt is forecasted to grow to USD 27.38 million by 2034, with 17.60% share and 2.96% CAGR through national child nutrition initiatives.
• Nigeria: Nigeria will attain USD 21.06 million by 2034, accounting for 13.51% share and a CAGR of 2.92% from expanding vitamin accessibility in rural zones.

List of Top Vitamin K Companies

• Lonza
• Bactolac Pharmaceutical Inc.
• Atlantic Essential Products Inc.
• Amway
• NOW Foods
• Amphastar Pharmaceuticals
• Stason Pharmaceuticals
• Seltzer Chemicals
• DSM
• BASF SE
• Archer Daniels Midland Co.
• Kyowa Hakko USA
• Nexeo Solutions
• Pfizer, Inc.
• Kappa Bioscience
• Bluestar Adisseo Co.
• Asiamerica Ingredients
• Country Life (Kikkoman Corporation)
• Livealth Biopharma

Top Two Companies with Highest Market Share:

• DSM held over 16% market share in 2024, leading in both Vitamin K1 and K2 product lines globally.
• BASF SE captured 12% of the market with advanced fermentation-based Vitamin K2 technologies and European distribution dominance.

Investment Analysis and Opportunities

The Vitamin K Market is witnessing strong investment flows, especially in R&D and production expansion. In 2024, over $290 million was allocated globally for K2 fermentation facilities. North America contributed 38% of total investment in vitamin K nutraceuticals. New manufacturing hubs in India and Malaysia increased production capacity by 27% compared to 2023. Public health agencies allocated over 40 million doses of vitamin K1 for neonatal usage in 2024. Investors are increasingly targeting AI-powered nutrition platforms, with vitamin K featuring prominently in customizable supplement packs. B2B contract manufacturing deals rose by 22%, with companies securing long-term raw material sources. The rise of vegan and organic supplement lines presents untapped opportunities across developed economies.

New Product Development

The Vitamin K Market has experienced robust new product development activity, especially between 2023 and 2025. Over 110 new formulations were launched globally, incorporating Vitamin K2 into multivitamin complexes and bone support blends. MK-7, the most bioavailable form of Vitamin K2, was present in over 65% of new product launches in 2024. Innovative delivery formats such as chewable tablets, soft gels, liquid sprays, and gummies have gained popularity, accounting for 28% of vitamin K supplement sales globally. North American brands introduced 37 new vitamin K supplements in 2024 alone.

Five Recent Developments

• DSM launched a new MK-7 based functional beverage additive in Q2 2024, aimed at the Asian market, contributing to a 12% increase in their K2 ingredient sales.
• Kappa Bioscience opened a new fermentation facility in Norway in late 2023, increasing their production capacity by 40% and enabling annual output of over 900 metric tons of Vitamin K2.
• Pfizer introduced a pediatric-focused Vitamin K1 injectable line in early 2024, expanding access to neonatal care kits in over 20 countries.
• BASF SE partnered with Indian pharma firms in 2023, resulting in over 18 co-developed formulations targeting osteoporosis and coagulation deficiencies.
• Amway launched an AI-powered vitamin customization platform in 2025, integrating Vitamin K2 into 31% of all recommended supplement plans through digital health profiling tools.

Report Coverage

The Vitamin K Market Report offers in-depth coverage of market size, market share, product segmentation, and geographic distribution, with a data-driven approach tailored for B2B decision-makers. It provides a full overview of trends across the pharmaceutical, nutraceutical, and skincare industries. The report includes breakdowns by type (Vitamin K1 and K2) and by application (Osteoporosis, VKCFD, Dermal Use, Prothrombin Deficiency, VKDB). Coverage spans global and regional insights, with detailed analysis for North America, Europe, Asia-Pacific, and the Middle East & Africa.

Vitamin K Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1200.05 Million in 2026
Market Size Value By	USD 1954.37 Million by 2035
Growth Rate	CAGR of 5.57% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Vitamin K1 Vitamin K2 By Application : Osteoporosis Vitamin-K Dependent Clotting Factor Deficiency [VKCFD] Dermal Applications Prothrombin Deficiency Vitamin K Deficiency Bleeding [VKDB]
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample